Thermo Fisher Scientific Opens Doe & Ingalls Northeast cGMP Chemical Distribution Facility
Thermo Fisher Scientific Inc. has announced the opening of its new Doe & Ingalls Northeast cGMP chemical distribution facility to meet the growing demand for quality compliance, production chemical storage and supply chain services for the biopharmaceutical, life science and advanced technology markets.
“A secure, robust supply chain is crucial for manufacturers to remain competitive, reduce total cost of ownership and mitigate risk of supply interruption,” said Jeff Jochims, president, research and safety markets, Thermo Fisher Scientific. “Our new Doe & Ingalls facility offers customers the ability to ramp up or expand their production capabilities quickly and cost-efficiently. By leveraging our scale and depth of capabilities in production materials supply chain, our customers can focus their internal resources on what they do best — developing new pharmaceuticals and technologies.”
Located in Peabody, Mass., the 56,000 sq ft, state-of-the-art facility is designed to protect raw material integrity, control the flow of goods and deliver supply chain services. The facility is cGMP-compliant to assure products and processes are in strict compliance with regulatory agencies and meet and/or exceed standards for temperature control, audit log/documentation and product handling/sampling. Innovative supply chain services include
• Storage and warehousing of chemical and raw materials
• Dip tube exchange and temperature-controlled 2-8°C cold storage
• ISO Class 8 and Class 100 cleanrooms provide sampling services for sourcing and quality control (QC) testing of production chemical materials.
“We welcome and celebrate this expansion,” said Massachusetts Governor Deval Patrick. “This facility underscores Thermo Fisher’s commitment to the leading life sciences supercluster in the world.”
“We congratulate Thermo Fisher on the opening of the Doe & Ingalls site,” said Robert K. Coughlin, president and chief executive officer of MassBio, a life sciences trade organization. “This site will be an excellent resource for our members, many of whom are challenged to operate as a GMP-compliant operation when it’s time to scale up to pilot manufacturing. This facility will provide critical services to get them up and running, shortening the time it takes to get new products to market and to the patients who need them.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...